OMass Therapeutics’ Founder & Scientific Advisor, Professor Carol Robinson, receives a Royal Society Medal

July 23, 2019

Oxford, 23 July 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today announced that the Company’s Founder, Professor Carol Robinson, has been awarded a Royal Society Medal.

The Royal Medal was awarded to Carol for her pioneering work on structural biology improving the understanding of proteins, their interactions and functional regulation. The Royal Medals are one of the Royal Society’s most prestigious awards that recognise exceptional researchers who make outstanding contributions to science and are made annually on behalf of the Queen.

Professor Dame Carol Robinson, Founder & Scientific Advisor, OMass Therapeutics commented:
“I am truly honoured to be acknowledged with this award. Over the years, I have been present at several Royal Society Medal Award ceremonies and have always been very impressed by the recipients. I am delighted to be joining this distinguished group of scientists.”

– Ends –

Further information:

W Communications
Julia Wilson
+44(0)7818 430877

Notes for Editors:

About OMass Therapeutics
OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane proteins, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at:

Back To News

Related News

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
July 28, 2020

Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies…

Read More
OMass Announces Publication in Nature Methods
May 15, 2020

Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…

Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
February 25, 2020

– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…

Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
February 17, 2020

– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…

Read More